Concert Biopharmaceuticals Presents CTP-656 Phase 1 Data for Cystic Fibrosis Therapy at NACF Conference
Concert Pharmaceuticals will present data from a Phase 1 single ascending dose trial of experimental CF therapy CTP-656, a next generation potentiator developed for the treatment of cystic fibrosis during the 29th Annual North American Cystic Fibrosis Conference this week in Phoenix, Arizona. The study being presented is entitled ”…